mrg002
Showing 1 - 10 of 10
Advanced or Metastatic Urothelium Cancer Trial in Beijing (MRG002, Docetaxel Injection, Paclitaxel Injection)
Not yet recruiting
- Advanced or Metastatic Urothelium Cancer
- MRG002
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Feb 22, 2023
Breast Cancer With Liver Metastases Trial in Beijing, Guangzhou (MRG002)
Recruiting
- Breast Cancer With Liver Metastases
- MRG002
-
Beijing, Beijing, China
- +1 more
May 6, 2022
Advanced Solid Tumor Trial in Shanghai (MRG002)
Recruiting
- Advanced Solid Tumor
- MRG002
-
Shanghai, Shanghai, ChinaShanghai Oriental Hospital
Dec 2, 2021
Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer Trial in Beijing, Changsha, Shanghai
Recruiting
- Locally Advanced Gastric Cancer
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- MRG002
-
Beijing, Beijing, China
- +2 more
Feb 21, 2022
Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer Trial in
Recruiting
- Advanced Solid Tumors
- +2 more
- MRG002
-
Orange, California
- +5 more
May 4, 2022
Non-small- Cell Lung Cancer (NSCLC) Trial in Shanghai (MRG002)
Not yet recruiting
- Non-small- Cell Lung Cancer (NSCLC)
- MRG002
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Nov 19, 2021
Advanced or Metastatic Biliary Tract Cancer Trial in China (MRG002)
Recruiting
- Advanced or Metastatic Biliary Tract Cancer
- MRG002
-
Bengbu, Anhui, China
- +6 more
Dec 8, 2021
Advanced or Metastatic Breast Cancer Trial in Beijing, Shijiazhuang (MRG002)
Recruiting
- Advanced or Metastatic Breast Cancer
- MRG002
-
Beijing, Beijing, China
- +1 more
Jun 28, 2021
Advanced Breast Cancer, Metastatic Breast Cancer Trial in China (MRG002)
Recruiting
- Advanced Breast Cancer
- Metastatic Breast Cancer
- MRG002
-
Hefei, Anhui, China
- +18 more
Nov 29, 2021
Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma Trial in China (MRG002)
Recruiting
- Locally Advanced Urothelial Cancer
- Metastatic Urothelial Carcinoma
- MRG002
-
Hefei, Anhui, China
- +35 more
Dec 13, 2021